Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Published:2016-06 Issue:6 Volume:17 Page:738-746
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Sartore-Bianchi Andrea,Trusolino Livio,Martino Cosimo,Bencardino Katia,Lonardi Sara,Bergamo Francesca,Zagonel Vittorina,Leone Francesco,Depetris Ilaria,Martinelli Erika,Troiani Teresa,Ciardiello Fortunato,Racca Patrizia,Bertotti Andrea,Siravegna Giulia,Torri Valter,Amatu Alessio,Ghezzi Silvia,Marrapese Giovanna,Palmeri Laura,Valtorta Emanuele,Cassingena Andrea,Lauricella Calogero,Vanzulli Angelo,Regge Daniele,Veronese Silvio,Comoglio Paolo M,Bardelli Alberto,Marsoni Silvia,Siena Salvatore

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Cancer genome landscapes;Vogelstein;Science,2013

2. Comprehensive molecular characterization of human colon and rectal cancer;Network;Nature,2012

3. The genomic landscape of response to EGFR blockade in colorectal cancer;Bertotti;Nature,2015

4. Metastatic colorectal cancer: current state and future directions;Fakih;J Clin Oncol,2015

5. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study;Moroni;Lancet Oncol,2005

Cited by 802 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the therapeutic promise of drug-repurposed-loaded nanocarriers: A pioneering strategy in advancing colorectal cancer treatment;International Journal of Pharmaceutics;2024-10

2. Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?;Critical Reviews in Oncology/Hematology;2024-10

3. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10

4. Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas;Cancers;2024-09-13

5. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier;Cancer Treatment Reviews;2024-09